{"name":"Optinose US Inc.","slug":"optinose-us-inc","ticker":"","exchange":"","domain":"optinoseus.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"OPN-375","genericName":"OPN-375","slug":"opn-375","indication":"Gastroparesis (diabetic and idiopathic)","status":"phase_3"}]}],"pipeline":[{"name":"OPN-375","genericName":"OPN-375","slug":"opn-375","phase":"phase_3","mechanism":"OPN-375 is a selective serotonin 5-HT4 receptor agonist that enhances gastric motility and accelerates gastric emptying.","indications":["Gastroparesis (diabetic and idiopathic)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOdW5tS1RtcGw5aVhqa1Nubi14Y3JCSkhJRlNFdlJHSDg3Smw5eXFxY05GOHNKb0xERnR0NGpKbzFZTmV0YVRqQVpXQWl5Rm9KMDNvT3pyaTdUaThrM2t2YVFDNjBMVUZPcVVIZk1WTnpVeDMxYXUybDEyZVplZkZ6R2oxNXNVOURqeThucXQ5aWNpQXNpb3B4UWY5T1FmekFJZnR4OUNmcmJlUTF0VFBfVnlkTTBEdWxfYktFT2VYWHJab3J3SmJ4MTRSNXRsRnU4ajJJbGZZZ1NVQlNZcVNVMHN3MUs5b2J6RVhqTXh0TGswVzRTZnAzNjlvSERHY00?oc=5","date":"2026-04-07","type":"pipeline","source":"The Globe and Mail","summary":"Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors - The Globe and Mail","headline":"Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPR0dRbFYtMDF6UDNLVG92OXplUWN0dFcyUy0wdExYSERVa3JheTFnVC14eWw0bjM1aDVSM293cmFtY0RjOWVPbmJ1SUVDVmtfaGJ5cVRfOEZGNkJ0ZER6MFFBbXZIb1RReGRlQW1VZlpDZDItVjNLNEV6ZC03cXBIWlBR?oc=5","date":"2025-05-22","type":"pipeline","source":"Pharmaceutical Technology","summary":"Paratek expands commercial portfolio with acquisition of Optinose - Pharmaceutical Technology","headline":"Paratek expands commercial portfolio with acquisition of Optinose","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQZWdicVoyNTFjRW9DemlVTmNUUVRPTllJVmhoYUZXdm40Y1hKekU4X1gyaTVEUThCMUJqU0xrWFZBRzR5SHAtSHJRVkdValhSdWtFTzdGODctVjVVQzJfUUw3NE02WllSUE5PNXFZeF9oVEJvUjl2d084Y2IyYi1pNWtyVUFTNWVDb2w1c3I3WWdCazRiMmY1cmdSc0EyeVR5NWdfQzREbkhjQjhobC1pdEhKcUI3TUdpcVU0TENvVDRDRDVKbjR3NnYxRjd0bkpzbGtfb0J6Qzk5Zw?oc=5","date":"2025-05-22","type":"pipeline","source":"Akin","summary":"Akin Advised Pharmakon in its Debt Financing for Optinose’s Sale to Paratek Pharmaceuticals - Akin","headline":"Akin Advised Pharmakon in its Debt Financing for Optinose’s Sale to Paratek Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOWUZhY0MwalM0TVRMb3p1b0tmMnZMV3Y2ZzQ4eUhuQkdCbzJXeVZkRTJab0VxNF9zenRYdkVDbTZMV0VjUmVWbGhIRmhXOG9VUmZKZHBYVWNITWk0Z2ZFTDRCdVFHcG52cG1rRXE4al9RYUpZU0F5TFZZMEdkN0UwR3FIcWhsNGVIbkxTZUl5NXpnNHNPY200aHNaQ1UzNGNoYjFzSg?oc=5","date":"2025-03-21","type":"pipeline","source":"TradingView","summary":"Darden Restaurants, Nike, Optinose - TradingView","headline":"Darden Restaurants, Nike, Optinose","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQd18xV25Wbi1YOWdlTVJLdVF4eTJjNUpsaXhLN01Ga3AxMWdWOFk4bmpYQnhvbTgyZ0RndHFyeWtjSkljYUlWMFNveFZoS2ppUHMtMWFXQUNpZlpaSlZMYUxpVlp4RU04WGdpdXlCMGQ2eDJDWWZOdnc2VHBQdG5KLXlDWkJSZ3lIOE5CemFsRG5XNDVnRGtjYXRrWQ?oc=5","date":"2025-03-20","type":"deal","source":"BioSpace","summary":"Paratek Broadens Portfolio With OptiNose Buy Worth up to $330M - BioSpace","headline":"Paratek Broadens Portfolio With OptiNose Buy Worth up to $330M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQUnFSbjVZdnhyMmlYNG1xcl83YVkyazZxcEVRMnZ2QjRIT2M2WkJPb0dRX2ZHc19Wcl9EYmRHNV90b3pVc2d2eTdXVi1Od0x6YmRUUzZuQlVpQXBKcFNUVGxyeEJyNHpCNzRISi1DMVYzR3AzTF90YTNRX0VuN29SdFRvWQ?oc=5","date":"2025-03-20","type":"deal","source":"The Pharma Letter","summary":"Paratek to buy Optinose for up to $330 million - The Pharma Letter","headline":"Paratek to buy Optinose for up to $330 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQUUJIVWxCcFpvZXAwTm1VY2NLZC12NmxLLVBNOTVNaFpoZ0xmTkl3N1RtU1Zyelh1SDlGaEpNeGVxWDJaVDJRTUJyOTlxTHd4V1Uxd0lfOTNLYTIydVhGUFcxT2hVbWl4UjNzSE43VHd1WFd6OVQ0V3pocGdIZ3NfbnE2OUhtTlZsTl84Vlh3WkRzNU10VWlCU2xuZw?oc=5","date":"2024-07-02","type":"pipeline","source":"InvestorPlace","summary":"7 Little-Known Penny Stocks That Can Turn $10K Into $1 Million - InvestorPlace","headline":"7 Little-Known Penny Stocks That Can Turn $10K Into $1 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxPTVQ3TGpWNFBtTmV4aHFNU3ZfUG9jazB6Zkgwc29DNnJXd0JMWnhUeElmYkFEd0tlTWZsQmU0TlFWakd2VTkzNXY5M1RNLV96MmVOU3N6eWpTZmJYUDlhVGxvYnAyd0RQM1Y0bFhQY0NNWUZScG01a1NIYXVPVU1sSXJ2ZEoxWkp4WkQxaHQxbzdhS3VKOHZZTVpMamRRR25fOXE5REFGWnJEbi1PZEViNmdEWmhyY0REUmZpSHYwNGc2WGk4MV9sZTNnRC1laXRMeUFMclVXWUoyTzVZOThz?oc=5","date":"2024-05-10","type":"earnings","source":"GlobeNewswire","summary":"Optinose Announces Reporting Date for First Quarter 2024 Financial Results - GlobeNewswire","headline":"Optinose Announces Reporting Date for First Quarter 2024 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPSXZNZEVuaEh1RTA1LVY5SzgxNC1abzJkbk5YbVFiRnQzWW96aGtybVFWb3Y3N0pvNkVrVTRnTkZad3p6OHU1aXkxVFhTdm5mM1dLQmhRWEtWR0VKMEJmYzJvTFp4OGo1ODhrYXMwOGx5UEJYSENjdENibVQwNmNyQUwxSnh4czNCWTVzUGlSTk1kbjVLc2VpR25YT09ybGxxbjFqZHVJTnF2cnlkdTNSZA?oc=5","date":"2024-04-29","type":"regulatory","source":"The Business Journals","summary":"After key Xhance approval, Optinose outlines plan to quadruple sales and reach profitability - The Business Journals","headline":"After key Xhance approval, Optinose outlines plan to quadruple sales and reach profitability","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9CMkZCVV9WOWNWTXFGUzl5UEx2LTZzZkY5SERrRmNRVGdpU2FMZmwzdDh6b05yVUd5OEV4MGVFSTQ2WjRuWlhjdzlsWnNIZUlrTEJuYXd2aGtpYzMtdWdZekpKaFNhVnp0bDczeU5RMTU3a3cyTTl2Q3kxZGg0Zw?oc=5","date":"2021-09-28","type":"pipeline","source":"Allied Market Research","summary":"Nasal Polyps Treatment Market Size | Industry Growth, 2030 - Allied Market Research","headline":"Nasal Polyps Treatment Market Size | Industry Growth, 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1DSVc1MGpLZWUwYjVZUTZVZktEelB4STVraWFsbTQ5UmMzTEN4VlpXUkszU3VUZTN6NG5Ra1BPVThVVWtOTmFCak5lNlR0ZElVWnVGbnZiOUJfZENMeV9tdlpENFZfUUlXMVRkUDF3?oc=5","date":"2019-09-13","type":"trial","source":"QuotedData","summary":"BioPharma lends up to $150m to OptiNose - QuotedData","headline":"BioPharma lends up to $150m to OptiNose","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPMTZMR3dJdWp2OHVEOWdibEw1cGlGTjJ2ZmMxV2J2bTNhUlo4UnVOS3lXU2Z2LWx4LWNRWHlJTnJHOTNOTko4VzExQUt0bXo4dlJsRFlSdkY0MUs0dDNiR2RWdTcycUJtVUlUc29aamVReVNWckZLb2I0Nm9ObGp5WFVqN0E0Rl85SG0tU0xDM1VJZk9kRm53dTlXeHZRUTU5eWxSTHM2Wl9mbnBxZ0FON2hzeGM0Y3pzYnFxWkdTR0YtRGl0dHZIbWt5bWp0Z1haWGtkdTVsRjJTeEZ1dXFlSk55Q0dVelN0?oc=5","date":"2018-12-11","type":"deal","source":"PR Newswire","summary":"Avanir Pharmaceuticals Announces Termination of License Agreement with Optinose for ONZETRA® Xsail® - PR Newswire","headline":"Avanir Pharmaceuticals Announces Termination of License Agreement with Optinose for ONZETRA® Xsail®","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}